Intelligent Bio Solutions earnings release, May 14, 2026

Intelligent Bio Solutions Inc. (INBS) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Intelligent

Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales

Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance

Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period

NEW

YORK, May 13, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update.

“The third quarter marked another period of strong commercial execution and revenue growth,” said Harry Simeonidis, President and CEO at INBS. “Cartridge revenue increased 59% year-over-year and accounted for 66% of Q3 revenue, confirming that customer utilization patterns align with our recurring revenue, razor-razorblade business model. Nine-month revenue of $3.07 million reflects consistent and compounding growth, and the business is continuing to strengthen ahead of important FDA regulatory milestones and our anticipated entry into the multi-billion-dollar U.S. market.”

“Our results this quarter and over the past nine months demonstrate that we are delivering on our core business fundamentals,” said

Spiro Sakiris, CFO at INBS. “Q3 gross margin was over 50%, up from 47% a year ago. This growth was driven by operational efficiencies and increased sales volumes. Our value-driven pricing structure has also remained consistent, as customers recognize the efficiency and cost-effectiveness of our fingerprint drug screening technology compared to traditional methods. Our nine-month marketing investment of $1.77 million has been a direct contributor to our 39% revenue growth and successful capital raising of $14.67 million (net of issuance costs), and we are now seeing improved marketing efficiency in Q3, with the quarter’s spend down 42% year-over-year while commercial momentum continues to accelerate.”

Product

Revenue Breakdown

Three

Months Ended March 31, 2026 (Q3 Fiscal 2026):

Nine

Months Ended March 31, 2026:

Fiscal

Third Quarter and Nine Months Ended March 31, 2026, and Subsequent Highlights

Throughout the fiscal third quarter, INBS’s growing installed base continued to drive recurring consumable demand. Crossing the 50% gross margin threshold for the first time is a significant operational milestone, reflecting the increasing contribution of higher-margin cartridge sales and the efficiencies being realized through the Company’s new manufacturing partnership.

The

Company’s strategic investment in marketing over the nine-month period has proven its value, contributing directly to revenue growth and successful capital raising, with Q3 marketing spend down 42% year-over-year as brand awareness and market presence continue to mature.

For the nine months ended March 31, 2026, cartridge revenue continued to grow as a proportion of total revenue, with gross margin improvement of approximately 800 basis points year-over-year underscoring the improving unit economics of the business as it scales.

INBS’s proprietary Intelligent Fingerprinting Drug Screening System continues to gain traction across more than 27 countries, serving hundreds of customers in construction, manufacturing, transportation, mining, and other safety-critical industries where non-invasive, rapid drug screening delivers compelling operational value. With a clearly functioning razor-razorblade commercial model, expanding gross margins, record nine-month revenue, and a regulatory pathway progressing toward the multi-billion-dollar U.S. market, management believes the

Company is well-positioned to deliver continued growth through the remainder of fiscal 2026. and beyond.

About

Intelligent Bio Solutions Inc.

Intelligent

Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The

Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.

With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025Nine Months Ended March 31, – 2026Nine Months Ended March 31, – 2025
Revenue1,060,802728,8673,069,3732,208,648
Cost of revenue (exclusive of amortization shown separately below)-525,421-387,499-1,555,962-1,297,366
Gross profit535,381341,3681,513,411911,282
Other incomeGovernment support income165,695173,271431,682433,039
Operating expensesSelling, general and administrative expenses-2,458,605-2,414,639-7,512,388-6,195,490
Operating expensesDevelopment and regulatory approval expenses-893,979-358,351-1,902,261-1,814,047
Operating expensesDepreciation and amortization-290,393-301,978-875,667-907,577
Operating expensesImpairment of long-lived assets-5,200-294,127
Operating expensesTotal operating expenses-3,648,177-3,074,968-10,584,443-8,917,114
Operating expensesLoss from operations-2,947,101-2,560,329-8,639,350-7,572,793
Other income (expense), netInterest expense-4,241-7,919-7,435-21,027
Other income (expense), netRealized foreign exchange gain (loss)32,258-11332,258-914
Other income (expense), netInterest income49,44417,68763,28292,464
Other income (expense), netTotal other income (expense), net77,4619,65588,10570,523
Other income (expense), netNet loss-2,869,640-2,550,674-8,551,245-7,502,270
Other income (expense), netNet loss attributable to non-controlling interest-6,928-7,148-27,93723,641
Other income (expense), netNet loss attributable to Intelligent Bio Solutions Inc.-2,862,712-2,543,526-8,523,308-7,478,629
Other comprehensive income (loss)Foreign currency translation gain (loss)-233,631116,007-171,766189,197
Other comprehensive income (loss)Total other comprehensive income (loss)-233,631116,007-171,766189,197
Other comprehensive income (loss)Comprehensive loss-3,103,271-2,434,667-8,723,011-7,313,073
Other comprehensive income (loss)Comprehensive loss attributable to non-controlling interest-6,928-7,148-27,937-23,641
Other comprehensive income (loss)Comprehensive loss attributable to Intelligent Bio Solutions Inc.-3,096,343-2,427,519-8,695,074-7,289,432
Other comprehensive income (loss)Net loss per share, basic and diluted*-1.8-4.41-7.54-15.92
Other comprehensive income (loss)Weighted average shares outstanding, basic and diluted*1,594,496577,1911,129,973469,849

Balance Sheet

As of March 31, — Condensed Consolidated Balance Sheets

As of March 31, – 2026 – (Unaudited)As of June 30, – 2025
Current assetsCash and cash equivalents6,862,2041,019,909
Current assetsAccounts receivable, net878,357594,614
Current assetsInventories597,469635,215
Current assetsResearch and development tax incentive receivable568,600734,408
Current assetsAssets held for sale327,500
Current assetsPrepaid expenses and other current assets843,090826,976
Current assetsTotal current assets9,749,7204,138,622
Current assetsProperty and equipment, net312,276251,325
Current assetsOperating lease right-of-use assets1,801,62269,520
Current assetsIntangibles, net2,999,1743,790,319
Current assetsTotal assets14,862,7928,249,786
Current liabilitiesAccounts payable and accrued expenses3,635,7194,534,246
Current liabilitiesCurrent portion of operating lease liabilities388,74684,659
Current liabilitiesCurrent employee benefit liabilities586,637534,990
Current liabilitiesNotes payable197,146
Current liabilitiesTotal current liabilities4,611,1025,351,041
Current liabilitiesEmployee benefit liabilities, less current portion40,69684,921
Current liabilitiesOperating lease liabilities, less current portion1,459,678
Current liabilitiesTotal liabilities6,111,4765,435,962
Shareholders’ equityCommon stock, $0.01 par value, 100,000,000 shares authorized, 2,001,185 and 2,001,173 shares issued and outstanding, as of March 31, 2026, respectively; 732,338 and 732,326 shares issued and outstanding, as of June 30, 2025, respectively*20,0127,323
Shareholders’ equityTreasury stock, at cost, 12 shares as of March 31, 2026 and June 30, 2025, respectively*-1-1
Shareholders’ equityAdditional paid-in capital*80,497,63765,849,823
Shareholders’ equityAccumulated deficit-71,056,373-62,533,065
Shareholders’ equityAccumulated other comprehensive loss-499,710-327,944
Shareholders’ equityTotal consolidated Intelligent Bio Solutions Inc. equity8,961,5652,996,136
Shareholders’ equityNon-controlling interest-210,249-182,312
Shareholders’ equityTotal shareholders’ equity8,751,3162,813,824
Shareholders’ equityTOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY14,862,7928,249,786
Full release

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals, and timelines to enter the U.S. market, among others. Although Intelligent

Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual... (truncadiffer materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,”

“plans,” “projects,” “intends,” “potential,” “may,” “could,”

“might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the

U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release.

Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company

Contact

Intelligent

Bio Solutions Inc. info@ibs.inc

Investor

& Media Contact

Valter

Pinto, Managing Director

KCSA Strategic Communications

PH: (212) 896-1254

INBS@kcsa.com

Financial

Tables to Follow

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Balance Sheets

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Statements of Operations and Other Comprehensive Income (Loss)*

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Intelligent Bio Solutions earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.